Epstein-barr virus serology as a potential screening marker for nasopharyngeal carcinoma among high-risk individuals from multiplex families in Taiwan

Cancer Epidemiology Biomarkers and Prevention

Volumn 23, Issue 7, 2014, Pages 1213-1219

  Coghill, Anna E ^a   Hsu, Wan Lun ^b,c   Pfeiffer, Ruth M ^a   Juwana, Hedy ^f   Yu, Kelly J ^a   Lou, Pei Jen ^d   Wang, Cheng Ping ^d   Chen, Jen Yang ^e   Chen, Chien Jen ^b,c   Middeldorp, Jaap M ^f   Hildesheim, Allan ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c GENOMICS RESEARCH CENTER   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^e NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^f VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; EARLY ANTIGEN P138; EARLY ANTIGEN P47; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 1; IMMUNOGLOBULIN A ANTIBODY; UNCLASSIFIED DRUG; VIRUS CAPSID ANTIGEN 18; EBV-ENCODED NUCLEAR ANTIGEN 1; IMMUNOGLOBULIN A; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CANCER DIAGNOSIS; CANCER SCREENING; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS; FALSE POSITIVE RESULT; FAMILY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NASOPHARYNX CARCINOMA; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROLOGY; TAIWAN; AGED; AREA UNDER THE CURVE; BLOOD; COMPLICATION; EARLY DIAGNOSIS; EPSTEIN BARR VIRUS INFECTION; LABORATORY DIAGNOSIS; MIDDLE AGED; NASOPHARYNX TUMOR; PROCEDURES; RECEIVER OPERATING CHARACTERISTIC; VIROLOGY;

ADULT; AGED; ANTIBODIES, VIRAL; AREA UNDER CURVE; EARLY DETECTION OF CANCER; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPSTEIN-BARR VIRUS INFECTIONS; EPSTEIN-BARR VIRUS NUCLEAR ANTIGENS; FALSE POSITIVE REACTIONS; HUMANS; IMMUNOGLOBULIN A; MALE; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; ROC CURVE; SENSITIVITY AND SPECIFICITY; TAIWAN;

EID: 84903986978     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-1262     Document Type: Article

References (28)

1. Raab-Traub N. Epstein-Barr virus in the pathogenesis of NPC. Semin Cancer Biol 2002;12: 431-1.
2. Raab-Traub N. Novel mechanisms of EBV-induced oncogenesis. Curr Opin Virol 2012;2: 453-8.
3. Young LS, Rickinson AB. Epstei-Barr virus: 40 years on. Nat Rev Cancer 2004;4: 757-68.
4. de-The G, Lavoue MF, Muenz L. Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate, and low incidence areas. IARC Sci Publ 1978: 471-81.
5. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer 1976;17: 1-7.
6. Hildesheim A, Levine PH. Etiology of nasopharyngeal carcinoma: a review. Epidemiol Rev 1993;15: 466-5.
7. Lanier A, Bender T, Talbot M, Wilmeth S, Tschopp C, Henle W, et al. Nasopharyngeal carcinoma in Alaskan Eskimos Indians, and Aleuts: a review of cases and study of Epstein-Barr virus, HLA, and environmental risk factors. Cancer 1980;46: 2100-6.
8. Burgos JS. Involvement of the Epstein-Barr virus in the nasopharyngeal carcinoma pathogenesis. Med Oncol 2005;22: 113-1.
9. Lo AK, Dawson CW, Jin DY, Lo KW. The pathological roles of BART miRNAs in nasopharyngeal carcinoma. J Pathol 2012;227: 392-03.
10. Niedobitek G, Agathanggelou A, Nicholls JM. Epstein-Barr virus infection and the pathogenesis of nasopharyngeal carcinoma: viral gene expression, tumour cell phenotype, and the role of the lymphoid stroma. Semin Cancer Biol 1996;7: 165-74.
11. Chien YC, Chen JY, Liu MY, Yang HI, Hsu MM, Chen CJ, et al. Serologic markers of Epstein-Barr virus infection and nasopharyngeal carcinoma in Taiwanese men. N Engl J Med 2001;345: 1877-82.
12. Ji MF, Wang DK, Yu YL, Guo YQ, Liang JS, Cheng WM, et al. Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma. Br J Cancer 2007;96: 623-0.
13. Cao SM, Liu Z, Jia WH, Huang QH, Liu Q, Guo X, et al. Fluctuations of Epstein-Barr virus serological antibodies and risk for nasopharyngeal carcinoma: a prospective screening study with a 20-year follow-up. PLoS ONE 2011;6: e19100.
14. Yu KJ, Hsu WL, Pfeiffer RM, Chiang CJ, Wang CP, Lou PJ, et al. Prognostic utility of anti-EBV antibody testing for defining NPC risk among individuals from high-risk NPC families. Clin Cancer Res 2011; 17: 1906-4.
15. Chang C, Middeldorp J, Yu KJ, Juwana H, Hsu WL, Lou PJ, et al. Characterization of ELISA detection of broad-spectrum anti-Epstein-Barr virus antibodies associated with nasopharyngeal carcinoma. J Med Virol 2013;85: 524-9.
16. Pickard A, Chen CJ, Diehl SR, Liu MY, Cheng YJ, Hsu WL, et al. Epstein-Barr virus seroreactivity among unaffected individuals within high-risk nasopharyngeal carcinoma families in Taiwan. Int J Cancer 2004;111: 117-3.
17. Yu KJ, Hsu WL, Chiang CJ, Cheng YJ, Pfeiffer RM, Diehl SR, et al. Cancer patterns in nasopharyngeal carcinoma multiplex families in Taiwan. Int J Cancer 2009;124: 1622-5.
18. Fachiroh J, Paramita DK, Hariwiyanto B, Harijadi A, Dahlia HL, Indrasari SR, et al. Single-Assay combination of Epstein-Barr Virus (EBV) EBNA1-And viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G(IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening. J Clin Microbiol 2006;44: 1459-67.
19. Hildesheim A, Anderson LM, Chen CJ, Cheng YJ, Brinton LA, Daly AK, et al. CYP2E1 genetic polymorphisms and risk of nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst 1997;89: 1207-2.
20. Wentzensen N, Wacholder S. From differences in means between cases and controls to risk stratification: a business plan for biomarker development. Cancer Discov 2013;3: 148-7.
21. Stevens SJ, Verkuijlen SA, Hariwiyanto B, Harijadi, Paramita DK, Fachiroh J, et al. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA. Int J Cancer 2006;119: 608-4.
22. Kovalchik SA, Tammemagi M, Berg CD, Caporaso NE, Riley TL, Korch M, et al. Targeting of low-dose CT screening according to the risk of lung-cancer death. N Engl J Med 2013;369: 245-4.
23. Liu Z, Ji MF, Huang QH, Fang F, Liu Q, Jia WH, et al. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China. Am J Epidemiol 2013;177: 242-0.
24. Zeng Y, Zhang LG, Li HY, Jan MG, Zhang Q, Wu YC, et al. Serological mass survey for early detection of nasopharyngeal carcinoma in Wuzhou City, China. Int J Cancer 1982;29: 139-1.
25. Zeng Y, Zhang LG, Wu YC, Huang YS, Huang NQ, Li JY, et al. Prospective studies on nasopharyngeal carcinoma in Epstein-Barr virus IgA/VCA antibody-positive persons in Wuzhou City, China. Int J Cancer 1985;36: 545-7.
26. Zeng Y, Zhong JM, Li LY, Wang PZ, Tang H, Ma YR, et al. Follow-up studies on Epstein-Barr virus IgA/VCA antibody-positive persons in Zangwu County, China. Intervirology 1983;20: 190-4.
27. Zong YS, Sham JS, Ng MH, Ou XT, Guo YQ, Zheng SA, et al. Immunoglobulin A against viral capsid antigen of Epstein-Barr virus and indirect mirror examination of the nasopharynx in the detection of asymptomatic nasopharyngeal carcinoma. Cancer 1992;69: 3-7.
28. Liu Y, Huang Q, Liu W, Liu Q, Jia W, Chang E, et al. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China. Int J Cancer 2012;131: 406-6.